Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program-Reference-Cited by-同舟云学术

Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program

Published:2021-02 Issue:3 Volume:22 Page:137-144
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Dong Olivia M¹²^ORCID,Bates Jill¹³,Chanfreau-Coffinier Catherine⁴,Naglich Michael⁵,Kelley Michael J¹⁶⁷,Meyer Laurence J⁸⁹,Icardi Michael⁸,Vassy Jason L¹⁰¹¹,Sriram Peruvemba¹²,Heise Craig William¹³¹⁴,Rivas Salvador¹³,Ribeiro Maria¹⁵¹⁶,Jacobitz Russell¹²,Rozelle Susan¹²,Chapman Jennifer G⁵,Voora Deepak¹²

Affiliation:

1. Durham VA Health Care System, Durham, NC 27705, USA

2. Department of Medicine, Duke Center for Applied Genomics & Precision Medicine, Duke University School of Medicine, Durham, NC 27708, USA

3. Division of Practice Advancement & Clinical Education, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

4. VA Informatics & Computing Infrastructure (VINCI), Salt Lake City, UT 84148, USA

5. Institute for Medical Research, Durham VA Medical Center, Durham, NC 27705, USA

6. Department of Medicine, Duke University Medical Center, Durham, NC 27708, USA

7. Department of Veterans Affairs, National Oncology Program Office, Office of Specialty Care, Durham, NC 27705, USA

8. Department of Veterans Affairs, Washington, DC 20571, USA

9. Department of Dermatology, University of Utah, UT 84112, USA

10. VA Boston Healthcare System, Boston, MA 02130, USA

11. Harvard Medical School, Boston, MA 02115, USA

12. North Florida/South Georgia Veterans Health System, Gainesville, FL 32608, USA

13. Phoenix VA Health Care System, Phoenix, AZ 85012, USA

14. The University of Arizona College of Medicine – Phoenix, Phoenix, AZ 85004, USA

15. Atlanta VA Medical Center, Atlanta, GA 30033, USA

16. Department of Hematology & Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA

Abstract

In 2019, the Veterans Affairs (VA), the largest integrated US healthcare system, started the Pharmacogenomic Testing for Veterans (PHASER) clinical program that provides multi-gene pharmacogenomic (PGx) testing for up to 250,000 veterans at approximately 50 sites. PHASER is staggering program initiation at sites over a 5-year period from 2019 to 2023, as opposed to simultaneous initiation at all sites, to facilitate iterative program quality improvements through Plan-Do-Study-Act cycles. Current resources in the PGx field have not focused on multisite, remote implementation of panel-based PGx testing. In addition to bringing large scale PGx testing to veterans, the PHASER program is developing a roadmap to maximize uptake and optimize the use of PGx to improve drug response outcomes.

Funder

Sanford Health

National Human Genome Research Institute

Mr. Denny Sanford

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2020-0173

Reference20 articles.

1. Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee